Endocrine Abstracts

The efficacy and safety of saxagliptin – a potent, selective dipeptidyl peptidase-4 (DPP-4) inhibitor, specifically designed for extended inhibition of the DPP-4 enzyme – was investigated in two double-blind, randomised trials (CV181-014/Study 1 and CV181-039/Study 2), either as add-on therapy in patients with type 2 diabetes mellitus (T2DM) inadequately controlled by metformin alone (HbA1c 7.0–10.0%) or as initial combination therapy with metformin i...